Clinical Research Directory

Key inclusion criteria * Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) * ECOG performance status of 0 or 1. * Patients with advanced or metastatic disease who completed at least 16 weeks of standard of care systemic chem-/chemoradiotherapy and achieved a partial response or stable disease. * Patients who underwent confirmed R0 or R1 resection and completed at least 3 months of combined peri-adjuvant multiagent chemotherapy. * No evidence of disease progression or recurrence. * Start of study treatment within 12 weeks from the last curative treatment (resected PDAC). * Patient must have completed 8-12 cycles of FOLFIRINOX or mFOLFIRINOX either as adjuvant, neoadjuvant, or perioperative (Part C) * Life expectancy at least 12 months (resected PDAC), or at least 6 months (advanced/metastatic PDAC). * Archival tumor tissue availability for central KRAS analysis and research. Key exclusion criteria * Not yet recovered from surgery (resected PDAC). * Gastro-intestinal bowel obstruction. * Other malignancy within the last 3 years. * Prior chemotherapy or targeted small molecule therapy within 14 (locally advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment. * Prior radiotherapy within 14 days (advanced/metastatic PDAC). No prior radiotherapy. in resected PDAC * Prior use of immunotherapeutic agents, including but not limited to checkpoint inhibitors or VSV-based agents. * Diagnosis of immunodeficiency, and/or history of allogeneic organ transplant * Chronic systemic treatment with steroids or other immunosuppressive medications. * Active autoimmune disease requiring systemic treatment within the last 2 years. * Chronic or concurrent active infectious disease requiring systemic antibodies, antifungal, or antiviral treatment * Major (according to the Investigator's judgment) surgery within 12 weeks from initiation of study treatment * Use of Tamoxifen within 1 month prior to start of study treatment